Menu
Search
|

Menu

Close
X

Exact Sciences Corp EXAS.OQ (NASDAQ Stock Exchange Capital Market)

105.44 USD
-0.00 (-0.00%)
As of Sep 18
Previous Close 105.44
Open 107.02
Volume 847,080
3m Avg Volume 541,134
Today’s High 107.02
Today’s Low 104.46
52 Week High 123.94
52 Week Low 53.09
Shares Outstanding (mil) 129.14
Market Capitalization (mil) 15,182.85
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.42 Mean rating from 12 analysts

KEY STATS

Revenue (mm, USD)
FY19
362
FY18
454
FY17
266
FY16
99
EPS (USD)
FY19
-0.955
FY18
-1.432
FY17
-2.037
FY16
-1.646
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
24.36
7.90
Price to Book (MRQ)
vs sector
19.82
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
64.53
17.64
LT Debt to Equity (MRQ)
vs sector
64.53
12.61
Return on Investment (TTM)
vs sector
-16.42
12.69
Return on Equity (TTM)
vs sector
-29.25
17.13

EXECUTIVE LEADERSHIP

Kevin Conroy
Chairman of the Board, President, Chief Executive Officer, Since 2014
Salary: $695,800.00
Bonus: $794,952.00
Jeffrey Elliott
Chief Financial Officer, Since 2016
Salary: $400,000.00
Bonus: $228,500.00
Mark Stenhouse
President, Cologuard, Since 2018
Salary: $375,000.00
Bonus: $285,625.00
D. Scott Coward
Senior Vice President, Chief Administrative Officer, General Counsel, Secretary, Since 2018
Salary: $446,923.00
Bonus: $268,488.00
Graham Lidgard
Senior Vice President, Chief Scientific Officer, Since 2009
Salary: $463,600.00
Bonus: $264,832.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

441 Charmany Dr
MADISON   WI   53719-1234

Phone: +1608.2845700

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

SPONSORED STORIES